The development of Personalised Host Response Diagnostic kit
Ended · Israel
Source: EU Funding & Tenders Portal
Drug resistance is a major reason for failure in cancer chemotherapy and/or modern targeted drugs. While tumours usually initially respond to therapy, resistance occurs within several cycles of treatments, or later on when patients are off therapy. Until recently, acquired and intrinsic resistance mechanisms for therapy were thought to be solely tumour driven. They are usually measured after tumou
- Status
- Closed
- Location
- Israel
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about The development of Personalised Host Response Diagnostic kit
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Drug resistance is a major reason for failure in cancer chemotherapy and/or modern targeted drugs. While tumours usually initially respond to therapy, resistance occurs within several cycles of treatments, or later on when patients are off therapy. Until recently, acquired and intrinsic resistance mechanisms for therapy were thought to be solely tumour driven. They are usually measured after tumours relapse or after several lines of treatments. However, in our ERC starting grant (HostResponse No. 260633), we found a novel way to predict resistance to therapy, already after 24 hours after the first drug administration. This discovery resulted in a new stream of research by means of published papers and the formation of special interest groups in cancer research and pharmaceutical disciplines that tackle this paradigm shift in cancer therapy. During our discussions with the cancer community, a clear need has emerged for a Specific Host-Driven Resistant Mechanisms (SHDRM®) diagnostic platform which will serve two (closely connected) markets:(1) the research community – enabling researchers to further examine this new paradigm; and (2) Clinicians- enabling oncologists to identify each patient specific host driven resistance mechanism and repurpose off-the-shelf drugs to counteract the specific factor driving the resistance. PHRD goal is to technically validate and develop a diagnostic platform Prototype for both markets including a clinical study design report which will enable to secure our partners including drug manufacturers, diagnostic providers, and the research community to commit to jointly push the new PHRD standard. |
Location
Country | Israel |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
